title: Intraperitoneal therapy for ovarian cancer: analysis of fluid distribution by computerized tomography.
abstract: Nineteen patients with ovarian cancer and minimal residual or persistent disease who were treated with cisplatin or carboplatin-based intraperitoneal (IP) regimens had distribution studies of IP contrast and computerized tomography prior to and during treatment. The distribution pattern was assessed retrospectively and scored for the presence of contrast in each of eight regions: the under surface of right and left diaphragms, the right and left paracolic gutters, the lesser omental sac, the intramesenteric region and the true and false pelvis. Assigning a point to each region with adequate distribution, we classified 10 patients to an excellent pattern (greater than or equal to 7 of 8 regions), 6 to a good pattern (5 to less than 7 regions), and 3 to an inadequate distribution pattern (less than 5 regions). Serial studies were performed in 8 patients after more than 4 cycles of IP therapy. In these patients, all of whom were tolerating treatment without progression, the distribution remained virtually unchanged for those with excellent distribution. One of three with good distribution manifested inadequate distribution on repeat study, and one of two with inadequate distribution improved to show a good pattern. In this small study there was no correlation of distribution patterns with plasma CA-125 at onset of IP treatment and prior surgical procedures or placement of the catheter tip. However, three patients with unsatisfactory patterns had procedures consisting of catheter placement only rather than formal reassessment laparotomies for ovarian cancer. Since satisfactory IP distribution may be required for obtaining a therapeutic advantage from IP therapy, methods for its assessment must be developed.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Medicine, University of Southern California, Los Angeles.
authors.forename: F M
authors.initials: FM
authors.lastname: Muggia
authors.forename: E
authors.initials: E
authors.lastname: LePoidevin
authors.forename: S
authors.initials: S
authors.lastname: Jeffers
authors.forename: C
authors.initials: C
authors.lastname: Russell
authors.forename: W
authors.initials: W
authors.lastname: Boswell
authors.forename: C P
authors.initials: CP
authors.lastname: Morrow
authors.forename: J
authors.initials: J
authors.lastname: Curtin
authors.forename: J
authors.initials: J
authors.lastname: Schlaerth
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001202:Ascitic Fluid / Q000378:metabolism*; D005260:Female; D006801:Humans; D007274:Injections, Intraperitoneal; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D014057:Tomography, X-Ray Computed